V
Veritas Aortic Solutions
Single implant for treating complex aortic diseases.
About Veritas Aortic Solutions
Veritas Aortic Solutions is a medical-device spinout from inQB8 Medical Technologies developing the Transcatheter Valved Aortic Root Conduit (TVARC) system — a single permanent implant combining a bioprosthetic aortic valve, an ascending aortic graft, and proprietary coronary perfusion ports, delivered via catheter through the femoral artery. The company is targeting non-surgical treatment for complex aortic root and ascending aortic diseases, conditions for which open-heart surgery remains the only approved option and where combined mortality and morbidity rates can reach as high as 65% for acute cases. Veritas completed prototyping, bench testing, and chronic animal studies within inQB8 before spinning out, and is preparing for first-in-human clinical use.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Headquarters
- Costa Mesa, United States
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, medical implants, Surgery, Cardiology and cardiovascular
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Veritas Aortic Solutions.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jun 2026 | $12M | $48M | Cedars-Sinai | ↗ |
| CORPORATE SPINOUT✓Other financing | Dec 2025 | $0 | — | inQB8 Medical Technologies | ↗ |
Growth signals
Latest recorded traffic for Veritas Aortic Solutions is 370 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 AndramedMinimally invasive devices for complex vascular interventions. |
Reutlingen, Germany | Acquired | 5 | — | — |
 Encore Medical Inc.Transcatheter devices for heart septal defect closure. |
United States | Operational | |||
 BioXgenECM cardiac patch reducing post-operative surgical complications. |
Tucson, United States | Operational | |||
 Mountain's 11 Innovation StudioRapid MedTech prototype development for early-stage validation. |
Flagstaff, United States | Operational | |||
 EMBOSCIPolymer embolic devices for predictable vessel occlusion. |
— | Operational | |||
 QUT HeartbeatsStudent-led development of a Total Artificial Heart. |
Brisbane, Australia | Operational | |||
 Advanced Interventional Cardiovascular (AIC) SolutionsNovel devices for endovascular and cardiac interventions. |
— | Operational | |||
 Sutra Medical, Inc.Transcatheter hemi-valve for mitral valve disease treatment. |
Lake Forest, United States | Operational |
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Cedars-Sinai
Series B and later1 investor entered at this stage
inQB8 Medical Technologies
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Veritas Aortic Solutions on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Veritas Aortic Solutions’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.